Literature DB >> 15605290

Highlights of the Annual Congress of the European Association of Nuclear Medicine, Helsinki 2004, and a dash of horizon scanning.

Peter J Ell1.   

Abstract

The Annual Congress of the European Association of Nuclear Medicine represents the major scientific and professional event in the field of nuclear medicine in Europe. Specialists from all allied professions meet to discuss the latest findings and discoveries. A very large industrial exhibition demonstrates the latest technological innovations and developments. This Highlights Lecture summarises the scientific and medical advances discussed at this important gathering. The lecture covers a significant proportion of the data presented and/or discussed in up-to-date reviews, and places some of the trends encountered in the context of the evolution of the field as a whole. There is much food for thought in most areas of nuclear medicine: advances in instrumentation and data processing, progress in radiochemistry and pharmacy, novel diagnostics and therapeutics, and new insights in known areas of clinical application such as neurology and psychiatry, cardiology, oncology, endocrine disorders, paediatrics, nephro-urology and musculoskeletal disorders. This Highlights Lecture is, however, only a brief resume of the vast amount of data discussed, which can be found in much greater detail in the Congress Proceedings, published as volume 31, supplement 2 of Eur J Nucl Med Mol Imaging in August 2004.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15605290     DOI: 10.1007/s00259-004-1720-9

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  7 in total

Review 1.  Impact of technology on the utilisation of positron emission tomography in lymphoma: current and future perspectives.

Authors:  D Visvikis; P J Ell
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-05-13       Impact factor: 9.236

2.  Gadolinium: named after Finland's most famous chemist.

Authors:  M L Wastie; K H Latief
Journal:  Br J Radiol       Date:  2004-02       Impact factor: 3.039

3.  A novel platform for radioimmunotherapy: extracorporeal depletion of biotinylated and 90Y-labeled rituximab in patients with refractory B-cell lymphoma.

Authors:  Ola Lindén; Jan Kurkus; Michael Garkavij; Eva Cavallin-Ståhl; Michael Ljungberg; Rune Nilsson; Tomas Ohlsson; Bengt Sandberg; Sven-Erik Strand; Jan Tennvall
Journal:  Cancer Biother Radiopharm       Date:  2005-08       Impact factor: 3.099

4.  Survival benefit after revascularization is independent of left ventricular ejection fraction improvement in patients with previous myocardial infarction and viable myocardium.

Authors:  Wanda Acampa; Mario Petretta; Letizia Spinelli; Marco Salvatore; Alberto Cuocolo
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-11-20       Impact factor: 9.236

5.  O-(2-[18F]fluoroethyl)-L-tyrosine PET for monitoring the effects of convection-enhanced delivery of paclitaxel in patients with recurrent glioblastoma.

Authors:  G Pöpperl; R Goldbrunner; F J Gildehaus; F W Kreth; P Tanner; M Holtmannspötter; J C Tonn; K Tatsch
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-05-05       Impact factor: 9.236

6.  Challenging the neuronal MIBG uptake by pharmacological intervention: effect of a single dose of oral amitriptyline on regional cardiac MIBG uptake.

Authors:  Montserrat Estorch; Ignasi Carrió; Esther Mena; Albert Flotats; Valle Camacho; Jordi Fuertes; Jaume Kulisewsky; Jagat Narula
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-06-19       Impact factor: 9.236

7.  Oestrogen-mediated regulation of somatostatin receptor expression in human breast cancer cell lines assessed with 99mTc-depreotide.

Authors:  B Van Den Bossche; E D'haeninck; F De Vos; R A Dierckx; S Van Belle; M Bracke; C Van de Wiele
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-03-17       Impact factor: 9.236

  7 in total
  1 in total

1.  Nuclear medicine, a paradigm of health and disease from 1985 to 2006?

Authors:  Georg Riccabona
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-12       Impact factor: 9.236

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.